ArticleCureus2025
Assessment of Mean Platelet Volume as an Inflammatory Marker in Chronic Obstructive Pulmonary Disease Exacerbations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) exacerbations significantly affect patients by worsening their health status, decreasing physical activity, and accelerating lung function decline. Mean platelet volume (MPV) serves as platelet function critical marker in inflammatory diseases, including COPD, where inflammation is pivotal. Recent studies evaluating this issue have yielded limited and controversial results. This work aimed to evaluate MPV as an inflammatory marker during COPD exacerbations.
methodsThis prospective study included 68 COPD patients diagnosed based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Cases were allocated equally into stable COPD and exacerbated COPD groups.
resultsInitial and follow-up MPV were significantly decreased among the exacerbation group in comparison to the stable group. A significant direct correlation was found between initial and follow-up MPV levels, while an inverse relationship was observed between MPV and total leukocyte count (TLC) in the exacerbation group.
conclusionMPV is a promising inflammatory marker in COPD exacerbations, demonstrating significant decreases during acute episodes. Its correlation with systemic inflammation supports its potential as a negative acute-phase reactant, warranting further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.